{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:28:45Z","timestamp":1792481325792,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the highly invasive nature of Glioblastoma (GB), complete surgical resection is not feasible, while motile tumour cells are often associated with several specific brain structures that enhance treatment-resistance. Here, we investigate the therapeutic potential of Disulfiram and Carbenoxolone, that inhibit two distinct interactions between GB and the brain tissue microenvironment: stress-induced cell-matrix adhesion and gap junction mediated cell-cell communication, respectively. Increase in cell numbers of tumour-initiating cells, which are cultured in suspension as cell clusters, and adherent differentiated cells can be blocked to a similar extent by Carbenoxolone, as both cell populations form gap junctions, but the adherent differentiated cells are much more sensitive to Disulfiram treatment, which \u2013 via modulation of NF-\u03baB signalling \u2013 interferes with cell-substrate adhesion. Interestingly, inducing adhesion in tumour-initiating cells without differentiating them does not sensitize for Disulfiram. Importantly, combining Disulfiram, Carbenoxolone and the standard chemotherapeutic drug Temozolomide reduces tumour size in an orthotopic mouse model. Isolating GB cells from their direct environment within the brain represents an important addition to current therapeutic approaches. The blockage of cellular interactions via the clinically relevant substances Disulfiram and Carbenoxolone, has distinct effects on different cell populations within a tumour, potentially reducing motility and\/or resistance to apoptosis.<\/jats:p>","DOI":"10.1038\/s41598-018-23592-z","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T01:55:42Z","timestamp":1522288542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach"],"prefix":"10.1038","volume":"8","author":[{"given":"Melanie","family":"Mettang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Meyer-Pannwitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Karpel-Massler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil O.","family":"Carragher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-6750","authenticated-orcid":false,"given":"Karl Josef","family":"F\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nonnenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Enzenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Dahlhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus D.","family":"Siegelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Stroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Fischer-Posovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Marion","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Eric","family":"Halatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-7100","authenticated-orcid":false,"given":"Mike-Andrew","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"23592_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-135","volume":"9","author":"C Krakstad","year":"2010","unstructured":"Krakstad, C. & Chekenya, M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9, 135 (2010).","journal-title":"Mol Cancer"},{"key":"23592_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-012-0798-3","volume":"108","author":"W Stummer","year":"2012","unstructured":"Stummer, W. et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108, 89\u201397 (2012).","journal-title":"J Neurooncol"},{"key":"23592_CR3","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1200\/JCO.2013.48.7546","volume":"32","author":"JD Hamilton","year":"2014","unstructured":"Hamilton, J. D. et al. Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escape. J Clin Oncol 32, e80\u201384 (2014).","journal-title":"J Clin Oncol"},{"key":"23592_CR4","first-page":"153","volume":"88","author":"A Giese","year":"2003","unstructured":"Giese, A. Glioma invasion\u2013pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumor suppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 88, 153\u2013162 (2003).","journal-title":"Acta Neurochir Suppl"},{"key":"23592_CR5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","volume":"5","author":"MD Walker","year":"1979","unstructured":"Walker, M. D., Strike, T. A. & Sheline, G. E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5, 1725\u20131731 (1979).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"23592_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ccr.2011.11.018","volume":"20","author":"CI Ene","year":"2011","unstructured":"Ene, C. I. & Fine, H. A. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 20, 695\u2013697 (2011).","journal-title":"Cancer Cell"},{"key":"23592_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"JT Huse","year":"2010","unstructured":"Huse, J. T. & Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10, 319\u2013331 (2010).","journal-title":"Nat Rev Cancer"},{"key":"23592_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/63.1.1","volume":"63","author":"HJ Scherer","year":"1940","unstructured":"Scherer, H. J. The forms of growth in Gliomas and their practical significance. Brain 63, 1\u201335 (1940).","journal-title":"Brain"},{"issue":"Pt 3","key":"23592_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1242\/jcs.109.3.631","volume":"109","author":"S Pullan","year":"1996","unstructured":"Pullan, S. et al. Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci 109(Pt 3), 631\u2013642 (1996).","journal-title":"J Cell Sci"},{"key":"23592_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.semcancer.2010.06.004","volume":"20","author":"C Box","year":"2010","unstructured":"Box, C., Rogers, S. J., Mendiola, M. & Eccles, S. A. Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol 20, 128\u2013138 (2010).","journal-title":"Semin Cancer Biol"},{"key":"23592_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.drup.2009.08.001","volume":"12","author":"MA Westhoff","year":"2009","unstructured":"Westhoff, M. A. & Fulda, S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat 12, 127\u2013136 (2009).","journal-title":"Drug Resist Updat"},{"key":"23592_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u201322072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology 15, 1100\u20131108 (2014).","journal-title":"The Lancet Oncology"},{"key":"23592_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1541-7786.MCR-13-0435-T","volume":"11","author":"MA Westhoff","year":"2013","unstructured":"Westhoff, M. A. et al. Inhibition of NF-kappaB signaling ablates the invasive phenotype of glioblastoma. Mol Cancer Res 11, 1611\u20131623 (2013).","journal-title":"Mol Cancer Res"},{"key":"23592_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ijc.10972","volume":"104","author":"W Wang","year":"2003","unstructured":"Wang, W., McLeod, H. L. & Cassidy, J. Disulfiram-mediated inhibition of NF-\u03baB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer 104, 504\u2013511 (2003).","journal-title":"International Journal of Cancer"},{"key":"23592_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-6-7","volume":"6","author":"R Oliveira","year":"2005","unstructured":"Oliveira, R. et al. Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biol 6, 7 (2005).","journal-title":"BMC Cell Biol"},{"key":"23592_CR16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93\u201398 (2015).","journal-title":"Nature"},{"key":"23592_CR17","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1038\/onc.2008.148","volume":"27","author":"MA Westhoff","year":"2008","unstructured":"Westhoff, M. A., Zhou, S., Bachem, M. G., Debatin, K. M. & Fulda, S. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 27, 5169\u20135181 (2008).","journal-title":"Oncogene"},{"key":"23592_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrn3060","volume":"12","author":"M Westphal","year":"2011","unstructured":"Westphal, M. & Lamszus, K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 12, 495\u2013508 (2011).","journal-title":"Nat Rev Neurosci"},{"key":"23592_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756\u2013760 (2006).","journal-title":"Nature"},{"key":"23592_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2990.2009.01008.x","volume":"35","author":"TC Johannessen","year":"2009","unstructured":"Johannessen, T. C. et al. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol 35, 380\u2013393 (2009).","journal-title":"Neuropathol Appl Neurobiol"},{"key":"23592_CR21","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/ijc.29908","volume":"138","author":"M Schneider","year":"2016","unstructured":"Schneider, M. et al. A paired comparison between glioblastoma \u201cstem cells\u201d and differentiated cells. Int J Cancer 138, 1709\u20131718 (2016).","journal-title":"Int J Cancer"},{"key":"23592_CR22","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1002\/ijc.29138","volume":"136","author":"L Nonnenmacher","year":"2015","unstructured":"Nonnenmacher, L. et al. RIST: A potent new combination therapy for glioblastoma. Int J Cancer 136, E173\u2013187 (2015).","journal-title":"Int J Cancer"},{"key":"23592_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1593\/neo.07112","volume":"9","author":"DR Rhodes","year":"2007","unstructured":"Rhodes, D. R. et al. Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia 9, 166\u2013180 (2007).","journal-title":"Neoplasia"},{"key":"23592_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.celrep.2015.04.021","volume":"11","author":"M Hitomi","year":"2015","unstructured":"Hitomi, M. et al. Differential connexin function enhances self-renewal in glioblastoma. Cell Rep 11, 1031\u20131042 (2015).","journal-title":"Cell Rep"},{"key":"23592_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/0008-5472.CAN-15-1286","volume":"76","author":"SF Murphy","year":"2016","unstructured":"Murphy, S. F. et al. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. Cancer Research 76, 139\u2013149 (2016).","journal-title":"Cancer Research"},{"key":"23592_CR26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1074\/jbc.M113.508390","volume":"289","author":"HT Le","year":"2014","unstructured":"Le, H. T. et al. Gap Junction Intercellular Communication Mediated by Connexin43 in Astrocytes Is Essential for Their Resistance to Oxidative Stress. Journal of Biological Chemistry 289, 1345\u20131354 (2014).","journal-title":"Journal of Biological Chemistry"},{"key":"23592_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/sj.bjp.0706102","volume":"144","author":"PE Martin","year":"2005","unstructured":"Martin, P. E., Wall, C. & Griffith, T. M. Effects of connexin-mimetic peptides on gap junction functionality and connexin expression in cultured vascular cells. Br J Pharmacol 144, 617\u2013627 (2005).","journal-title":"Br J Pharmacol"},{"key":"23592_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-10-27","volume":"10","author":"G Sohl","year":"2010","unstructured":"Sohl, G., Joussen, A., Kociok, N. & Willecke, K. Expression of connexin genes in the human retina. BMC Ophthalmol 10, 27 (2010).","journal-title":"BMC Ophthalmol"},{"key":"23592_CR29","doi-asserted-by":"publisher","first-page":"e21108","DOI":"10.1371\/journal.pone.0021108","volume":"6","author":"H Takeuchi","year":"2011","unstructured":"Takeuchi, H. et al. Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer\u2019s disease. PLoS One 6, e21108 (2011).","journal-title":"PLoS One"},{"key":"23592_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jneuroim.2011.09.012","volume":"240\u2013241","author":"L Endong","year":"2011","unstructured":"Endong, L. et al. The Gap-junction inhibitor Carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells. Journal of Neuroimmunology 240\u2013241, 58\u201364 (2011).","journal-title":"Journal of Neuroimmunology"},{"key":"23592_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nature09413","volume":"467","author":"FB Chekeni","year":"2010","unstructured":"Chekeni, F. B. et al. Pannexin 1 channels mediate \/\u2018find-me\/\u2019 signal release and membrane permeability during apoptosis. Nature 467, 863\u2013867 (2010).","journal-title":"Nature"},{"key":"23592_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.stem.2009.03.014","volume":"4","author":"SM Pollard","year":"2009","unstructured":"Pollard, S. M. et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4, 568\u2013580 (2009).","journal-title":"Cell Stem Cell"},{"key":"23592_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/1541-7786.MCR-13-0236","volume":"11","author":"LS Payne","year":"2013","unstructured":"Payne, L. S. & Huang, P. H. The Pathobiology of Collagens in Glioma. Molecular Cancer Research 11, 1129\u20131140 (2013).","journal-title":"Molecular Cancer Research"},{"key":"23592_CR34","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987\u2013996 (2005).","journal-title":"N Engl J Med"},{"key":"23592_CR35","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3892\/ol.2016.4113","volume":"11","author":"Y Iwadate","year":"2016","unstructured":"Iwadate, Y. Epithelial-mesenchymal transition in glioblastoma progression. Oncology Letters 11, 1615\u20131620 (2016).","journal-title":"Oncology Letters"},{"key":"23592_CR36","doi-asserted-by":"publisher","first-page":"e64169","DOI":"10.1371\/journal.pone.0064169","volume":"8","author":"H Zarkoob","year":"2013","unstructured":"Zarkoob, H., Taube, J. H., Singh, S. K., Mani, S. A. & Kohandel, M. Investigating the Link between Molecular Subtypes of Glioblastoma, Epithelial-Mesenchymal Transition, and CD133 Cell Surface Protein. PLOS ONE 8, e64169 (2013).","journal-title":"PLOS ONE"},{"key":"23592_CR37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.70359\/bhc2008v033p082","volume":"33","author":"H Kragh","year":"2008","unstructured":"Kragh, H. From Disulfiram to Antabuse: the invention of a drug. Bull Hist Chem 33, 82\u201388 (2008).","journal-title":"Bull Hist Chem"},{"key":"23592_CR38","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/bjc.2012.442","volume":"107","author":"P Liu","year":"2012","unstructured":"Liu, P. et al. Cytotoxic effect of disulfiram\/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 107, 1488\u20131497 (2012).","journal-title":"Br J Cancer"},{"key":"23592_CR39","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1158\/1078-0432.CCR-15-1798","volume":"22","author":"X Lun","year":"2016","unstructured":"Lun, X. et al. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clin Cancer Res 22, 3860\u20133875 (2016).","journal-title":"Clin Cancer Res"},{"key":"23592_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11060-007-9390-7","volume":"85","author":"B Raychaudhuri","year":"2007","unstructured":"Raychaudhuri, B., Han, Y., Lu, T. & Vogelbaum, M. A. Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 85, 39\u201347 (2007).","journal-title":"J Neurooncol"},{"key":"23592_CR41","doi-asserted-by":"crossref","unstructured":"Friedmann-Morvinski, D. et al. Targeting NF-kappaB in glioblastoma: A therapeutic approach. Sci Adv 2 (2016).","DOI":"10.1126\/sciadv.1501292"},{"key":"23592_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-128","volume":"10","author":"D Beier","year":"2011","unstructured":"Beier, D., Schulz, J. B. & Beier, C. P. Chemoresistance of glioblastoma cancer stem cells\u2013much more complex than expected. Mol Cancer 10, 128 (2011).","journal-title":"Mol Cancer"},{"key":"23592_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.18632\/oncotarget.969","volume":"4","author":"RE Kast","year":"2013","unstructured":"Kast, R. E. et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4, 502\u201330 (2013).","journal-title":"Oncotarget"},{"key":"23592_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-016-2104-2","volume":"128","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol 128, 259\u2013266 (2016).","journal-title":"J Neurooncol"},{"key":"23592_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5698\/1535-7511-12.2.66","volume":"12","author":"BW Connors","year":"2012","unstructured":"Connors, B. W. Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures. Epilepsy Currents 12, 66\u201368 (2012).","journal-title":"Epilepsy Currents"},{"key":"23592_CR46","doi-asserted-by":"publisher","first-page":"44852","DOI":"10.1074\/jbc.M305072200","volume":"278","author":"Y-W Zhang","year":"2003","unstructured":"Zhang, Y.-W., Kaneda, M. & Morita, I. The Gap Junction-independent Tumor-suppressing Effect of Connexin 43. Journal of Biological Chemistry 278, 44852\u201344856, https:\/\/doi.org\/10.1074\/jbc.M305072200 (2003).","journal-title":"Journal of Biological Chemistry"},{"key":"23592_CR47","first-page":"1561","volume":"61","author":"YK Wang","year":"2015","unstructured":"Wang, Y. K., Deng, F., Miao, J., Xie, H. & Feng, J. C. Neuroprotection by Carbenoxolone Against Ischemia Injury Involves PI3K\/Akt Pathway. Clin Lab 61, 1561\u20131568 (2015).","journal-title":"Clin Lab"},{"key":"23592_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbrc.2015.11.034","volume":"468","author":"J Kim","year":"2015","unstructured":"Kim, J., Jung, E. J., Moon, S. S. & Seo, M. Protective effect of carbenoxolone on ER stress-induced cell death in hypothalamic neurons. Biochem Biophys Res Commun 468, 793\u2013799 (2015).","journal-title":"Biochem Biophys Res Commun"},{"key":"23592_CR49","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1073\/pnas.0306996101","volume":"101","author":"TC Sandeep","year":"2004","unstructured":"Sandeep, T. C. et al. 11\u00ce\u00b2-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proceedings of the National Academy of Sciences of the United States of America 101, 6734\u20136739 (2004).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"23592_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrc1075","volume":"3","author":"P Friedl","year":"2003","unstructured":"Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3, 362\u2013374 (2003).","journal-title":"Nat Rev Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23592-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23592-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23592-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T01:49:58Z","timestamp":1751507398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23592-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23592"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23592-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"24 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5527"}}